戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 anism of hydrolysis of the nitrile (N-acetyl-phenylalanyl-2-amino-propionitrile, I) catalyzed by Gln1
2 namide (probe 1) and N,beta,beta-trimethyl-l-phenylalanyl-4-benzoyl-N-[(1S,2E)-3-carboxy-1-isop ropyl
3  in the PheATE catalyzed chemical pathway: L-phenylalanyl-adenosine-5'-monophosphate diester (L-Phe-A
4 t (by adenylation domain) as tightly bound L-phenylalanyl-adenosine-5'-monophosphate diester (L-Phe-A
5                Oxidization also enlarges the phenylalanyl-adenylate binding pocket but to a lesser ex
6  Michaelis complex through the AMP moiety of phenylalanyl-adenylate substrate.
7  supercooled water: the flipping kinetics of phenylalanyl and tyrosinyl rings of the 6 kDa protein BP
8                                              Phenylalanyl-arginine beta-naphthylamide (PAbetaN), is a
9      Each contains a photoreactive p-benzoyl-phenylalanyl (Bpa) residue in close proximity to the RGD
10 thin washed cells by N-(p-toluenesulfonyl)-l-phenylalanyl chloride derivatization with stable isotope
11 nti-proliferative effects of N-alpha-tosyl-l-phenylalanyl chloromethyl ketone (TPCK) have been known
12 esicles was inhibited by TPCK (tolylsullonyl phenylalanyl chloromethyl ketone), PMSF (phenylmethylsul
13 te-directed chymotryptic inhibitor N-tosyl-L-phenylalanyl-chloromethyl ketone (TPCK) suppressed DNA f
14 efficacy than the nonhydroxylated 4-(malonyl)phenylalanyl-containing congener in blocking the associa
15 as observed that the 4-(alpha-hydroxymalonyl)phenylalanyl-containing peptide exhibited greater effica
16 ipeptides of the methyl ester of 4-benzoyl-l-phenylalanyl-F(n)()Ys at pH 4 were examined with a nanos
17 otency when Xxx = 4-(phosphonodifluoromethyl)phenylalanyl (F2Pmp) (K(i) = 0.2 microM) and when Xxx =
18 specificities (valyl, methionyl, alanyl, and phenylalanyl) from higher plants or Escherichia coli wer
19 ically disordered proteins (IDPs) containing phenylalanyl-glycyl (FG)-rich repeats line the pore and
20                                          The phenylalanyl-glycyl-glycyl-alanyl-prolyl (FG-GAP) domain
21  Several ester derivatives of hydrocinnamoyl-phenylalanyl-homocysteine, one of the most potent PAM in
22             It was proposed that thaxtomin A phenylalanyl hydroxylation was catalyzed by the monooxyg
23           Six days of treatment with N-CBZ-L-phenylalanyl-L-alanine-diazomethylketone (ZPAD) resulted
24                  A 2-day exposure to N-CBZ-L-phenylalanyl-L-alanine-diazomethylketone (ZPAD), a selec
25 N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L- phenylalanine did not inhibit b
26 Another FPR antagonist, N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L- phenyla
27 ues for L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester HCl (MF13), were de
28 III, HCII, alpha1-proteinase inhibitor, or d-phenylalanyl-l-prolyl-l-arginine chloromethyl ketone.
29 samples anticoagulated with citrate versus D-phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPA
30 sted the binding of enzymatically inactive D-phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPA
31 ed with turbidimetric aggregometry in both D-phenylalanyl-L-prolyl-L-arginine chloromethylketone and
32 lood was collected in buffered citrate and D-phenylalanyl-L-prolyl-L-arginine chloromethylketone anti
33 the direct thrombin inhibitors hirudin and D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone, ind
34 a a tripeptide tether to yield fluorescein-D-phenylalanyl-L-prolyl-L-arginyl-fVIIa (Fl-FPR-fVIIa).
35 lysine-fluorescein and N-formyl-valyl-leucyl-phenylalanyl-lysine-fluorescein to the N-formyl peptide
36  Here, through comparative investigations of phenylalanyl, methionyl, and arginyl ternary complexes,
37 equilibrates the Calpha configuration of the phenylalanyl moiety presented as Phe-S-4'-phosphopanteth
38 ase may have structural homology, tyrosyl to phenylalanyl mutants of MAO A at positions 377, 402, 407
39 designated 4-benzoyl-N,beta,beta-trimethyl-l-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-i sopropylbut-2-e
40  site inhibitors, RWJ-50353 10080(N-methyl-D-phenylalanyl-N-[5-[(aminoiminomethyl)amino]-1- [[(2-benz
41 orescent peptide ligand CHO-norleucyl-leucyl-phenylalanyl-norleucyl-tyrosyl-lysine-fluorescein (CHO-N
42 inding kinetics of N-formyl-methionyl-leucyl-phenylalanyl-phenylalanyl-lysine-fluorescein and N-formy
43     However, strain S5T2H1 synthesized cyclo(phenylalanyl-prolyl) and niphimycin Ia, along with three
44 ns with the S1-S3 sites are similar to the D-phenylalanyl-prolyl-arginyl chloromethylketone structure
45 sociate with ribosomes in sucrose gradients: phenylalanyl-RS (FRS), and the 9 ARSs that form the mult
46                               Hydrocinnamoyl-phenylalanyl-(S-benzoyl-homocysteine) benzyl ester was i
47                                   Notably, a phenylalanyl side chain pointing toward the metal may hi
48 ic binding surface, not a pocket, for the P1 phenylalanyl side-chain of chymostatin.
49 12,15-N-dimethylcyclo-(L-4-nitrotryptophyl-L-phenylalanyl), the didehydroxy analog of thaxtomin A.
50 luoromethyl ketone (AcLF-CF3) and N-acetyl-L-phenylalanyl trifluoromethyl ketone (AcF-CF3) were deter
51 195 in chymotrypsin with N-acetyl-L-leucyl-L-phenylalanyl trifluoromethyl ketone (AcLF-CF3) and N-ace
52 ares 45% identity with the yeast cytoplasmic phenylalanyl tRNA synthetase (PheRS) regulatory alpha-su
53 ug resistance was engineered using a mutated phenylalanyl tRNA synthetase gene and marking strains wi
54 ion from fars-3, an essential subunit of the phenylalanyl tRNA synthetase.
55                 Inhibition of purified yeast phenylalanyl-tRNA synthetase (FRS) catalyzed aminoacylat
56 ficity in AcKRS and in a PylRS variant [iodo-phenylalanyl-tRNA synthetase (IFRS)] that displays both
57                          Human mitochondrial phenylalanyl-tRNA synthetase (mtPheRS) has been identifi
58 the amino acid binding and recognition step, phenylalanyl-tRNA synthetase (PheRS) faces the challenge
59                                              Phenylalanyl-tRNA synthetase (PheRS) is a multidomain (a
60                                              Phenylalanyl-tRNA synthetase (PheRS) maintains specifici
61                                              Phenylalanyl-tRNA synthetase (PheRS) preferentially liga
62                                  For example phenylalanyl-tRNA synthetase (PheRS) proofreads the non-
63 olutionary divergence of tyrosine editing by phenylalanyl-tRNA synthetase (PheRS) was used as a model
64 n its acceptor stem that prevents editing by phenylalanyl-tRNA synthetase (PheRS), leading to the acc
65  translation by the proofreading activity of phenylalanyl-tRNA synthetase (PheRS).
66  that of the heterotetrameric (alphabeta)(2) phenylalanyl-tRNA synthetase (PheRS).
67 ies of binding of phenylalanine analogues to phenylalanyl-tRNA synthetase (PheRS).
68 molog of one subunit of prokaryote and yeast phenylalanyl-tRNA synthetase (PheRS).
69 ynthetase (PylRS) is structurally related to phenylalanyl-tRNA synthetase (PheRS).
70                             A designed yeast phenylalanyl-tRNA synthetase (yPheRS (T415G)) activates
71 or tRNA (ytRNA(Phe)(CUA)) and a mutant yeast phenylalanyl-tRNA synthetase (yPheRS (T415G)) into an Es
72 -acetyllysyl-tRNA synthetase [AcKRS], 3-iodo-phenylalanyl-tRNA synthetase [IFRS], a broad specific Py
73  and the aminoacyl-tRNA hydrolytic domain of phenylalanyl-tRNA synthetase are functionally and evolut
74  we have engineered a Caenorhabditis elegans phenylalanyl-tRNA synthetase capable of tagging proteins
75 e we report that wild-type E. coli EF-Tu and phenylalanyl-tRNA synthetase collaborate with these muta
76 c azetidines targeting Plasmodium falciparum phenylalanyl-tRNA synthetase comprise one promising new
77                                          The phenylalanyl-tRNA synthetase editing mechanism is also a
78 crimination in vivo revealed that editing by phenylalanyl-tRNA synthetase is essential for faithful t
79                                 We show that phenylalanyl-tRNA synthetase misactivates tyrosine and t
80  computationally designed mutant form of the phenylalanyl-tRNA synthetase of the host.
81                                          The phenylalanyl-tRNA synthetase variants S57C and N280S bot
82          To define the mechanism of editing, phenylalanyl-tRNA synthetase was used to investigate dif
83 nthesized in nature (by Thermus thermophilus phenylalanyl-tRNA synthetase), and many disubstituted tR
84 n of the nucleus-encoded human mitochondrial phenylalanyl-tRNA synthetase, which aminoacylates hmt-tR
85  from the active site of human mitochondrial phenylalanyl-tRNA synthetase.
86 lanyl-tRNA is formed by Thermus thermophilus phenylalanyl-tRNA synthetase.
87 ines that inhibit a new antimalarial target, phenylalanyl-tRNA synthetase.
88 lyclonal antibodies raised against mammalian phenylalanyl-tRNA synthetase.
89 a proofreading ("editing") activity, such as phenylalanyl-tRNA synthetases (PheRS) that hydrolyze mis
90 tivity of aminoacyl-tRNA synthetases such as phenylalanyl-tRNA synthetases (PheRS), which edit misact
91                      In addition, seryl- and phenylalanyl-tRNA synthetases that are only marginally r
92 erminal module that resembles the OB-fold of phenylalanyl-tRNA synthetases.
93                                   The leucyl/phenylalanyl-tRNA-protein transferase (L/F-transferase)
94 ize aminoacyl-tRNA recognition by the leucyl/phenylalanyl-tRNA-protein transferase (L/Ftransferase).
95 tes diacetyl-[14C]lysyl-tRNA and acetyl-[14C]phenylalanyl-tRNA.